GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT01633970
- Locations
- 🇺🇸
Uni of Chicago, Chicago, Illinois, United States
🇺🇸Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville, North Carolina, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
- Conditions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1007
- Registration Number
- NCT01615068
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Allegheny General Hospital; Transplantation Services, Pittsburgh, Pennsylvania, United States
🇺🇸Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01613599
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Asthma&Allergy, Baltimore, Maryland, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT01609140
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
- Conditions
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 503
- Registration Number
- NCT01604252
- Locations
- 🇺🇸
Newport Dermatology and Laser Associates, Newport Beach, California, United States
🇺🇸Laser and Dermatologic Surgery Center, Chesterfield, Missouri, United States
🇺🇸Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT01602120
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇩🇪St. Franziskus Hospital, Munster, Germany
🇩🇪Universitatsklinikum Leipzig, Leipzig, Germany
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 276
- Registration Number
- NCT01598597
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01586195
- Locations
- 🇺🇸
Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Oncology Specialists, S.C., Park Ridge, Illinois, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 578
- Registration Number
- NCT01582503
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01577173